Clinical Trial Update: An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia [Phase 3]

View source ↗

Summary

An extension study (Phase 3) is being conducted to evaluate the efficacy and safety of Vosoritide (BMN 111) in children with Achondroplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• Vosoritide (vosoritide)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Achondroplasia | Phase 3 | Status: ACTIVE_NOT_RECRUITING